Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun;8(12):752. doi: 10.21037/atm-20-4072

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2020 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Tan-I combined with Paclitaxel inhibit cell migration of cancer cells. (A) Cell migration assay of A2780 and ID-8 cells by Transwell in control group, Tan-I group, PTX group, and combination group. A2780 and ID-8 cells were treated with Tan-I (4.8 μg/mL), Paclitaxel (0.1 μg/mL), or Tan-I combined with Paclitaxel for 24 hours. Cells were stained with 0.4% crystal violet. Magnification 100×. (B) Quantitative analysis in (A). Data are presented as the mean ± SD of three independent experiments. *, P<0.05 versus which Tan-I group or Paclitaxel group. (C) Migration assay of A2780 and ID-8 cells by wound healing in the control group, Tan-I group, PTX group, and combination group (magnification 100×). (D) The percentage of cell migration in (C). Data are presented as the mean ± SD of three independent experiments. *, P<0.05 versus which Tan-I group or Paclitaxel group.